Plasma Osteopontin Level as a Diagnostic Marker of Hepatocellular Carcinoma in Patients with Radiological Evidence of Focal Hepatic Lesions

Venook A.P. , Papandreou C. , Furuse J. , de Guevara L.L. : The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist, 15(Suppl 4): 5–13, 2010.

el-Zayadi A.R. , Badran H.M. , Barakat E.M. , Attia Mel D. , Shawky S. , Mohamed M.K. , Selim O. , Saeid A. : Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol, 11: 5193–5198, 2005.

Lehman E.M. , Wilson M.L. : Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer, 124: 690–697, 2009.

Sanyal A.J. , Yoon S.K. , Lencioni R. : The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist, 15(Suppl 4): 14–22, 2010.

El-Serag H.B. , Rudolph K.L. : Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132: 2557–2576, 2007.

Elsayes K.M. , Narra V.R. , Yin Y. , Mukundan G. , Lammle M. , Brown J.J. : Focal hepatic lesions: diagnostic value of enhancement pattern approach with contrast-enhanced 3D gradient-echo MR imaging. Radiographics, 25: 1299–1320, 2005.

Huang G.T. , Sheu J.C. , Yang P.M. , Lee H.S. , Wang T.H. , Chen D.S. : Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma—a study based on 420 patients. J Hepatol, 25: 334–338, 1996.

Durand F. , Regimbeau J.M. , Belghiti J. , Sauvanet A. , Vilgrain V. , Terris B. , Moutardier V. , Farges O. , Valla D. : Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol, 35: 254–258, 2001.

Daniele B. , Bencivenga A. , Megna A.S. , Tinessa V. : Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology, 127: S108–112, 2004.

Tan C.H. , Low S.C. , Thng C.H. : APASL and AASLD consensus guidelines on imaging diagnosis of hepatocellular carcinoma: a review. Int J Hepatol, 2011: 519783, 2011.

Bae J.S. , Park S.J. , Park K.B. , Paik S.Y. , Ryu J.K. , Choi C.K. , Hwang T.J. : Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma. Korean J Intern Med, 20: 80–85, 2005.

Villanueva A. , Minguez B. , Forner A. , Reig M. , Llovet J.M. : Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med, 61: 317–328, 2010.

Stefaniuk P. , Cianciara J. , Wiercinska-Drapalo A. : Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol, 16: 418–424, 2010.

Marrero J.A. , Feng Z. , Wang Y. , Nguyen M.H. , Befeler A.S. , Roberts L.R. , Reddy K.R. , Harnois D. , Llovet J.M. , Normolle D. , Dalhgren J. , Chia D. , Lok A.S. , Wagner P.D. , Srivastava S. , Schwartz M. : Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology, 137: 110–118, 2009.

Senger D.R. , Wirth D.F. , Hynes R.O. : Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell, 16: 885–893, 1979.

Thalmann G.N. , Sikes R.A. , Devoll R.E. , Kiefer J.A. , Markwalder R. , Klima I. , Farach-Carson C.M. , Studer U.E. , Chung L.W. : Osteopontin: possible role in prostate cancer progression. Clin Cancer Res, 5: 2271–2277, 1999.

Angelucci A. , Festuccia C. , Gravina G.L. , Muzi P. , Bonghi L. , Vicentini C. , Bologna M. : Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate, 59: 157–166, 2004.

Brown L.F. , Papadopoulos-Sergiou A. , Berse B. , Manseau E.J. , Tognazzi K. , Perruzzi C.A. , Dvorak H.F. , Senger D.R. : Osteopontin expression and distribution in human carcinomas. Am J Pathol, 145: 610–623, 1994.

Weber G.F. : The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta, 1552: 61–85, 2001.

Koopmann J. , Fedarko N.S. , Jain A. , Maitra A. , Iacobuzio-Donahue C. , Rahman A. , Hruban R.H. , Yeo C.J. , Goggins M. : Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev, 13: 487–491, 2004.

Fedarko N.S. , Jain A. , Karadag A. , Van Eman M.R. , Fisher L.W. : Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res, 7: 4060–4066, 2001.

Saeki Y. , Mima T. , Ishii T. , Ogata A. , Kobayashi H. , Ohshima S. , Ishida T. , Tabunoki Y. , Kitayama H. , Mizuki M. , Katada Y. , Asaoku H. , Kitano M. , Nishimoto N. , Yoshizaki K. , Maeda M. , Kon S. , Kinoshita N. , Uede T. , Kawase I. : Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol, 123: 263–270, 2003.

Pan H.W. , Ou Y.H. , Peng S.Y. , Liu S.H. , Lai P.L. , Lee P.H. , Sheu J.C. , Chen C.L. , Hsu H.C. : Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 98: 119–127, 2003.

Gotoh M. , Sakamoto M. , Kanetaka K. , Chuuma M. , Hirohashi S. : Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int, 52: 19–24, 2002.

Lin F. , Li Y. , Cao J. , Fan S. , Wen J. , Zhu G. , Du H. , Liang Y. : Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells. Mol Biol Rep, 38: 5205–5210, 2011.

Zhang C.H. , Xu G.L. , Jia W.D. , Ge Y.S. , Li J.S. , Ma J.L. , Ren W.H. : Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer, 130: 2685–2692, 2012.

Cao D.X. , Li Z.J. , Jiang X.O. , Lum Y.L. , Khin E. , Lee N.P. , Wu G.H. , Luk J.M. : Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol, 18: 3923–3930, 2012.

Korita P.V. , Wakai T. , Shirai Y. , Matsuda Y. , Sakata J. , Cui X. , Ajioka Y. , Hatakeyama K. : Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol, 39: 1777–1783, 2008.

Weber S.M. , Lee F.T. Jr. : Expanded treatment of hepatic tumors with radiofrequency ablation and cryoablation. Oncology (Williston Park), 19: 27–32, 2005.

Kaibori M. , Ishizaki M. , Saito T. , Matsui K. , Kwon A.H. , Kamiyama Y. : Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg, 198: 39–45, 2009.

Wayne J.D. , Lauwers G.Y. , Ikai I. , Doherty D.A. , Belghiti J. , Yamaoka Y. , Regimbeau J.M. , Nagorney D.M. , Do K.A. , Ellis L.M. , Curley S.A. , Pollock R.E. , Vauthey J.N. : Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg, 235: 722–730, 2002.

Bruix J. , Sherman M. : Diagnosis of small HCC. Gastroenterology, 129: 1364, 2005.

Cui B.K. , Zhang C.Q. , Zhang Y. , Yuan Y.F. , Zhang Y.Q. , Shi M. , Chen M.S. , Li S.P. , Li J.Q. : Osteopontin as a potential biomarker of metastasis and recurrence for hepatocellular carcinoma. Ai Zheng, 25: 876–879, 2006.

Xie H. , Song J. , Du R. , Liu K. , Wang J. , Tang H. , Bai F. , Liang J. , Lin T. , Liu J. , Fan D. : Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis, 39: 167–172, 2007.

Kim S.H. , Chung Y.H. , Yang S.H. , Kim J.A. , Jang M.K. , Kim S.E. , Lee D. , Lee S.H. , Lee D. , Kim K.M. , Lim Y.S. , Lee H.C. , Lee Y.S. , Suh D.J. : Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. Korean J Hepatol, 15: 320–330, 2009.

Giannelli G. , Fransvea E. , Trerotoli P. , Beaugrand M. , Marinosci F. , Lupo L. , Nkontchou G. , Dentico P. , Antonaci S. : Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta, 383: 147–152, 2007.

Durazo F.A. , Blatt L.M. , Corey W.G. , Lin J.H. , Han S. , Saab S. , Busuttil R.W. , Tong M.J. : Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol, 23: 1541–1548, 2008.

Saffroy R. , Pham P. , Reffas M. , Takka M. , Lemoine A. , Debuire B. : New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med, 45: 1169–1179, 2007.

Cho S. , Ryu K.M. , Hwang Y.J. , Lee E.B. : Prognostic factors for pulmonary metastasectomy in the treatment of hepatocellular carcinoma. J Thorac Oncol, 5: 1251–1254, 2012.

Kitano K. , Murayama T. , Sakamoto M. , Nagayama K. , Ueno K. , Murakawa T. , Nakajima J. : Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. Eur J Cardiothorac Surg, 41: 376–382, 2012.

Arrieta O. , Cacho B. , Morales-Espinosa D. , Ruelas-Villavicencio A. , Flores-Estrada D. , Hernandez-Pedro N. : The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer, 7: 28, 2007.

Kim J. , Ki S.S. , Lee S.D. , Han C.J. , Kim Y.C. , Park S.H. , Cho S.Y. , Hong Y.J. , Park H.Y. , Lee M. , Jung H.H. , Lee K.H. , Jeong S.H. : Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol, 101: 2051–2059, 2006.

Bruix J. , Sherman M. , Llovet J.M. , Beaugrand M. , Lencioni R. , Burroughs A.K. , Christensen E. , Pagliaro L. , Colombo M. , Rodes J. : Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 35: 421–430, 2001.

Abu El Makarem M.A. , Abdel-Aleem A. , Ali A. , Saber R. , Shatat M. , Rahem D.A. , Sayed D. : Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol, 10: 296–305, 2011.

Christiansen M. , Hogdall C.K. , Andersen J.R. , Norgaard-Pedersen B. : Alpha-fetoprotein in plasma and serum of healthy adults: preanalytical, analytical and biological sources of variation and construction of age-dependent reference intervals. Scand J Clin Lab Invest, 61: 205–215, 2001.

Denhardt D.T. , Giachelli C.M. , Rittling S.R. : Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol, 41: 723–749, 2001.

Koguchi Y. , Kawakami K. , Uezu K. , Fukushima K. , Kon S. , Maeda M. , Nakamoto A. , Owan I. , Kuba M. , Kudeken N. , Azuma M. , Yara S. , Shinzato T. , Higa F. , Tateyama M. , Kadota J. , Mukae H. , Kohno S. , Uede T. , Saito A. : High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. Am J Respir Crit Care Med, 167: 1355–1359, 2003.

Le Q.T. , Sutphin P.D. , Raychaudhuri S. , Yu S.C. , Terris D.J. , Lin H.S. , Lum B. , Pinto H.A. , Koong A.C. , Giaccia A.J. : Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res, 9: 59–67, 2003.

Matsui A. , Mochida S. , Ohno A. , Nagoshi S. , Hirose T. , Fujiwara K. : Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res, 29: 202–206, 2004.

Shang S. , Plymoth A. , Ge S. , Feng Z. , Rosen H.R. , Sangrajrang S. , Hainaut P. , Marrero J.A. , Beretta L. : Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology, 55: 483–490, 2012.

Plumer A. , Duan H. , Subramaniam S. , Lucas F.L. , Miesfeldt S. , Ng A.K. , Liaw L. : Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer. BMC Cancer, 8: 38, 2008.

Constantinescu D. , Vornicu M. , Grigoriu C. , Cozmei C. , Grigoriu B.D. : Assaying for circulating osteopontin in practice: a technical note. Eur Respir J, 35: 1187–1188, 2010.

Vordermark D. , Said H.M. , Katzer A. , Kuhnt T. , Hansgen G. , Dunst J. , Flentje M. , Bache M. : Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer, 6: 207, 2006.

Overgaard J. , Eriksen J.G. , Nordsmark M. , Alsner J. , Horsman M.R. : Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol, 6: 757–764, 2005.